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Abstract
Humans who harbor loss of function mutations in the actin-associated filamin B (FLNB) gene develop spondylocarpotarsal
syndrome (SCT), a disorder characterized by dwarfism (delayed bone formation) and premature fusion of the vertebral,
carpal and tarsal bones (premature differentiation). To better understand the cellular and molecular mechanisms governing
these seemingly divergent processes, we generated and characterized FlnB knockdown ATDC5 cell lines. We found that FlnB
knockdown led to reduced proliferation and enhanced differentiation in chondrocytes. Within the shortened growth plate
of postnatal FlnB2/2 mice long bone, we observed a similarly progressive decline in the number of rapidly proliferating
chondrocytes and premature differentiation characterized by an enlarged prehypertrophic zone, a widened Col2a1+/
Col10a1+ overlapping region, but relatively reduced hypertrophic zone length. The reduced chondrocyte proliferation and
premature differentiation were, in part, attributable to enhanced G2/M phase progression, where fewer FlnB deficient
ATDC5 chondrocytes resided in the G2/M phase of the cell cycle. FlnB loss reduced Cdk1 phosphorylation (an inhibitor of
G2/M phase progression) and Cdk1 inhibition in chondrocytes mimicked the null FlnB, premature differentiation phenotype,
through a b1-integrin receptor- Pi3k/Akt (a key regulator of chondrocyte differentiation) mediated pathway. In this context,
the early prehypertrophic differentiation provides an explanation for the premature differentiation seen in this disorder,
whereas the progressive decline in proliferating chondrocytes would ultimately lead to reduced chondrocyte production
and shortened bone length. These findings begin to define a role for filamin proteins in directing both cell proliferation and
differentiation through indirect regulation of cell cycle associated proteins.
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Introduction
Mutations in FLNB cause two types of skeletal dysplasias on the
basis of their clinical presentation and genetic etiology. Null alleles
of FLNB cause recessive spondylocarpotarsal syndrome (SCT;
OMIM 272460), which features dwarfism and fusion of the
vertebral, carpal, and tarsal bones. Autosomal dominant muta-
tions of FLNB (missense mutations, small in-frame deletions or
insertions) cause a group of skeletal dysplasias, including Larsen
syndrome (LS; OMIM 150250), atelosteogenesis I and III (AOI
and AOIII; OMIM 108720 and 108721), and boomerang
dysplasia (BD; OMIM 112310) [1,2,3]. LS features joint
dislocations, cervical spine malformations, and supernumerary
carpal and tarsal ossification centers [1]. AOI, AOIII, and BD
exhibit more severe phenotypes including undermodeled bones or
ossification initiation failure [2,3,4]. A minority of individuals
survive in AOIII, while AOI and BD present with fetal/perinatal
lethality.
Several studies have described the skeletal phenotypes seen with
loss of FlnB mouse models. In general, loss of FlnB function in
mice leads to two major skeletal phenotypes, dwarfism, and
premature mineralization with bone fusion [5,6]. We have
previously shown a progressive delay and shortening in formation
of the long bones, giving rise to the smaller stature seen in the null
mice [6]. Other FlnB mutant mice with truncation mutations (at
the N-terminal position1624 of the full-length 2602 amino acids)
developed early fusion of the spinal vertebrae, due to enhanced
chondrocyte hypertrophy and premature differentiation [5,7,8].
The mechanisms affecting these two apparently incongruent
processes of overall reduction in bone growth and premature
differentiation are not clear.
Longitudinal endochondrial bone growth is controlled by the
growth plate, which consists of columns of chondrocytes.
Chondrocytes progress through division, rotation, pushing forward
and differentiation into hypertrophic cells, which are then replaced
by osteocytes. In this respect, the rates of cell cycle progression and
timing of cell cycle exit will affect long bone growth. Cell cycle
progression is mediated by cyclin-dependent kinases (Cdks), their
activators, and inhibitors [9,10]. Multiple cell cycle genes have
been implicated in long bone growth, such as Cyclin D1 in
affecting G1 phase of cell cycle [11]. Filamins have been
implicated in regulation of Cdk1/Cyclin B, which affect the
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e89352
G2/M phase of cell cycle [12]. Moreover, several kinases (Aurora)
have been shown to influence cell fate within this same phase of
the cell cycle [13,14]. In this respect, G2 to M phase progression
through Cdk1/Cyclin B can potentially influence both cell
proliferation and differentiation.
We have previously shown that filamins can regulate cell
differentiation and proliferation through their association with cell
cycle associated proteins in mouse central nervous system [12].
More specifically, the smaller brain size seen in loss of Filamin A
(FlnA) mice results from a delayed differentiation of neural
progenitors and prolongation of the cell cycle in G2/M phase,
leading to slower proliferation rates [12]. In this report, we find
that loss of FlnB similarly leads to a shortening (albeit of the
skeletal long bones), and is also accompanied by a progressive
decline in the number of proliferating chondrocytes over time.
However, instead of delayed differentiation and a prolongation of
the cell cycle in G2/M phase giving rise to this shortening, as seen
with FlnA inhibition, FlnB knockout (FlnB2/2) mice show an
increase in early onset differentiation within the lower proliferative
and prehypertrophic zones, and this maturation is associated with
fewer rapidly proliferating chondrocytes. Fewer proliferating null
FlnB chondrocytes remain in the G2/M phase, suggestive of either
fewer cells entering this phase or more rapid progression through
G2/M. Similarly, enhanced chondrocyte maturation and a
reduction in proliferative rates are seen in stably transfected
ATDC5 chondrocytes lacking in FlnB. Loss of FlnB in the
ATDC5 cells further causes a downregulation of the G2/M phase
inhibitor phospho-Cdk1, and inhibition of phopho-Cdk1 promotes
G2/M phase progression and chondrocyte differentiation. Finally,
we show that FlnB can modulate Cdk1 phosphorylation through a
b1 integrin-Pi3k/Akt dependent pathway. These findings suggest
that loss of FlnB leads to premature chondrocyte differentiation
into the prehypertrophic state. Although prehypertrophic chon-
drocytes continue to proliferate, the increased maturity likely slows
chondrocyte proliferative rates, and produces fewer chondrocytes
over time, thereby producing the observed phenotypes of both
dwarfism and early differentiation.
Results
Decline in Chondrocyte Proliferation and Increased
Differentiation with FlnB Knockdown in vitro
Given the difficulty in studying primary chondrocyte cultures,
we generated several stable ATDC5 chondrocyte cell lines with
reduced FlnB expression through shRNA knockdown. Two target
sequences were designed (FlnBsh1 and FlnBsh2) and their
expression levels were gauged by EGFP tagged lentiviral
production and infection into ATDC5 cells (Supplementary
Material, Fig. S1A). Lines generated from several FlnA targeting
sequences and non-targeting sequences served as controls.
Infection with lentivirus carrying either shRNA sequence led to
downregulation of FlnB expression at both the mRNA and protein
levels (Supplementary Material, Fig. S1B). Both FlnBsh1 and
FlnBsh2 caused down-regulation of the premature chondrocyte
marker, Sox9, levels and up-regulation of the chondrocyte
differentiation marker, Runx2, in ATDC5 cells (Supplementary
Material, Fig. S1B). The FlnBsh2 sequence showed a higher
knockdown efficiency than FlnBsh1, and was therefore used
primarily to display the results from subsequent experiments,
although similar results were obtained from both lines. No changes
in cell death were seen in established cell lines.
To better understand the role of FlnB knockdown in effecting
chondrocyte differentiation, we examined the expression levels of
various chondrocyte markers for the proliferative (Collagen2
(Col2a1) and Sox9 [15,16]), prehypertrophic (parathyroid hor-
mone receptor 1 (Pthr1) and Indian hedgehog (Ihh) [17,18,19]),
and differentiation/hypertrophic zones(Collagen 10 (Col10a1)
[20,21] and Runx2 [22,23]). Sox9 and Col2a1 levels were
decreased (35.8% and 21.8%, respectively, versus control), while
the hypertrophic differentiation marker Col10a1 and the hyper-
trophic-required transcription factor Runx2, were increased
(314.8% and 110.4%, respectively, versus control) in FlnBsh2
cells as assessed by immunocytochemistry and western blot
analyses (Fig. 1A, B). The intermediate prehypertrophic markers,
Pthr1 and Ihh, were also decreased in the loss of FlnB cells (27.9%
and 29.3%, respectively, versus control), suggesting enhanced
differentiation with prolonged culturing in vitro. To further
characterize the differentiation, we performed alkaline phospha-
tase assay and found that the alkaline phosphatase activity was
decreased but not increased, which suggested that FlnB loss
promoted some but not all features of hypertrophic chondrocyte
differentiation (Fig. 1C).
To address the effect of FlnB loss on chondrocyte proliferative
rates, we plotted the growth curves for the respective cell lines and
used several proliferation markers (immunostaining of BrdU, Ki67
and phosphohistone H3 (PH3)). We observed a significant
reduction in the proliferative capacity (as gauged by cell number)
of the FlnBsh2 cultures over time (Fig. 1D). Approximately 20% of
FlnB knockdown cells incorporated BrdU as compared to 45% in
control ATDC5 cells after 1-hour incubation. Ki67 staining and
quantitative analyses showed that only 31% of FlnB knockdown
ATDC5 cells were Ki67hi compared with 67% in the control
group. Lastly, PH3 staining and analyses showed a similar trend
with 3.9% of the FlnBsh2 cells staining positive for the M phase
marker, compared with 8.7% in control (Fig. 1E). Collectively,
these results suggest that FlnB loss impairs chondrocyte prolifer-
ation while simultaneously promoting differentiation.
Loss of FlnB Leads to Postnatal Long Bone Shortening
Accompanied with Prehypertrophic Zone Widening
Previously we had focused on defects in chondrocyte migration
giving rise to a delay in bone growth, leading to shortened long
bones in embryonic FlnB2/2 mice [6]. However, these observa-
tions of delayed skeletogenesis would seemingly be inconsistent
with the premature chondrocyte differentiation seen in FlnB
knockdown ATDC5 cells. We therefore examined the long bone
development in early postnatal FlnB2/2 mice to ascertain whether
changes in chondrocyte development over time could reconcile
these differences. Consistent with our prior characterization of
embryonic FlnB2/2 mice, we observed a similar shortening of the
appendicular long bones in postnatal FlnB2/2mice (P1 to 8 weeks;
quantification analysis of 4 weeks and 8 weeks are shown in
Supplementary Material, Fig. S2A). The bone length was reduced
by approximately 1.4 mm at P1 and up to 4 mm by 8 weeks. The
length of the growth plate was significantly shortened in FlnB2/2
mice compared to age-matched controls (Supplementary Material,
Fig. S2B). Lastly, the ratio of Col10a1 to Col2a1 was also
decreased in the loss of FlnB postnatal mice, suggestive of an
overall delay (Supplementary Material, Fig. S3A, B). Overall,
these findings were consistent with a delay in skeletogenesis
(previously observed in the embryonic FlnB2/2 mice) and in
contrast with the early differentiation seen with FlnB knockdown
ATDC5 chondrocytes.
Changes in the rate of differentiation as chondrocytes progress
through the proliferative, prehypertrophic and hypertrophic zones
could potentially reconcile the precocious maturation but delay in
skeletal development, seen in chondrocytes with loss of FlnB
function. We therefore examined the expression of several
Filamin B Regulates Chondrocyte Development
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chondrocyte markers [24], including Sox9 and Col2a1 (less
differentiated/proliferative zone), Pthr1 and Ihh (intermediate
differentiation/prehypertrophic zone), Runx2 and Col10a1 (more
differentiated/hypertrophic zone) across different zones in the
growth plate of the long bones in postnatal mice. In the postnatal
null FlnB mice, we detected abnormally increased expression of
the hypertrophic markers Col10a1 (Supplementary Material, Fig.
S3A, C). Quantitative analysis of the Col10a1+ length/growth
plate length ratio at P1 age showed an 10% increase of the relative
width of the hypertrophic zone (38.7% in Flnb2/2 vs 28.5% in
wild type), which suggested that chondrocytes were undergoing
premature hypertrophic differentiation in FlnB2/2 long bone
(Supplementary Material, Fig. S3C). This trend toward early
maturation was seen at P7 and 2 weeks but was not statistically
significant suggesting a slowing of this process over time.
Additionally, fewer Sox9+ labeled chondrocytes were appreciated
with loss of FlnB (47.8% in FlnB2/2 vs 81.4% in wild type;
Supplementary Material, Fig. S4A) and increased signal intensity
for Runx2 was observed in the FlnB2/2 mice at P7 age (32.6 in
FlnB2/2 vs 28.9 luminosity in wild type; Supplementary Material,
Figure 1. Reduced proliferative capacity and enhanced differentiation in FlnB knockdown proliferating chondrocytes. (A)
Fluorescent immunocytochemistry performed on FlnB knockdown ATDC5 (FlnBsh2) chondrocytes shows downregulation of both proliferating
chondrocyte markers, Sox9 and Col2a1 in the FlnB knockdown ATDC5 cells. The immunostaining also shows down-regulation of the prehypertrophic
markers, Pthr1 and Ihh in the FlnB knocked down cells and increased expression for the hypertrophic marker Col10a1 and chondrocyte differentiation
marker Runx2 in FlnBsh2 proliferating chondrocytes. (B) Western blot analyses of FlnBsh2 chondrocytes show a similar increased differentiation of the
ATDC5 chondrocytes following FlnB knockdown compared to control. Results are graphically summarized to the right. (C) Alkaline phosphatase
assay. Alkaline phosphatase activity was decreased in FlnB knockdown ATDC5 cells. (D) FlnBsh2 chondrocytes undergo a slower growth rate
compared to normal ATDC5 cells. Quantification reveals an approximate 64% reduction in the proliferation rate by 5 days in culture. Cells are plated
at a density of 16105 and quantified at daily intervals. (E) Statistical analyses (n$3 independent samples per experiment) show that the numbers of
cells per unit area positively labeled for BrdU, Ki67, and PH3 (red) FlnBsh2 proliferating chondrocytes are decreased by 57%, 46%, and 45%,
respectively when compared to control ATDC5 cells. * = p,0.05, ** = p,0.01, *** = p,0.001. Scale bars = 50 mm.
doi:10.1371/journal.pone.0089352.g001
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Fig. S4B). These analyses were in contrast with observations of the
decreased Col10a1+ length relative to Col2a1+ length (suggestive
of delayed differentiation). This difference could potentially be
accounted for by the increase in overlap between Col10a1 and
Col2a1 in the loss of FlnB mice (Fig. 2A, and Supplementary
Material, Fig. S3A), indicating that more proliferative zone
chondrocytes (Col2a1+) were undergoing proliferative to prehy-
pertrophic transition. Immunostaining of the growth plates with
Pthr1 and Ihh demonstrated an increase in the prehypertrophic
zone in FlnB2/2 mice (Fig. 2B and C). The ratio of Pthr1+ length
to growth plate length, was increased (51.7% vs 39.2%, 38.7% vs
23.0% and 38.6% vs 28.1%, in FlnB2/2 vs wild type at P1, P7 and
2 weeks, respectively, Fig. 2B). Quantitative analysis showed that
the ratio of Ihh+ length/growth plate length, was increased (34.2%
vs 19.6% and 37.0% vs 27.7%, in FlnB2/2 and wild type, at P7
and 2 week old age, respectively, Fig. 2C). Both the increase in
Col2a1+-Col10a1+ overlapping expression and the increase in
Pthr1+ and Ihh+ zone would suggest that loss of FlnB promotes
premature prehypertrophic chondrocyte differentiation and/or
impairs transition from the prehypertrophic to hypertrophic zone.
Decline in Chondrocyte Proliferation and Increased Entry
of Chondrocytes into the Resting State with Loss of FlnB
Function in vivo
In general, a decrease in proliferation or increase in cell death
could explain bone shortening due to a fewer number of
chondrocytes. To address this possibility, we used markers for
cell proliferation (Sox9 and Ki67 for proliferating cells, BrdU for
cells in S-phase, and phospho-histone H3 (PH3) for cells in M-
phase). Immunostaining was performed on the radial bones of
FlnB2/2 mice at various ages, ranging from mid-embryonic
(E14.5) to 7 days postnatal (P7). There was a progressive reduction
in Sox9, BrdU, Ki67, and PH3 staining over time in FlnB2/2 mice
(Fig. 3). Although we did not see a significant difference between
WT and FlnB2/2 mice in our prior work [6] using BrdU labeling
at the E16.5 time point, we had observed a trend in a decrease in
the number of proliferating chondrocytes. This trend became
significant with increased sample numbers at this time point and
even more apparent at older postnatal ages. Although we observed
increased apoptosis along the periphery of the hypertrophic zone
along the perichondrium [6], no increase in cell death was
observed by TUNEL staining in the growth plates in proliferation
zone during these ages (data not shown). Overall, these findings
began to suggest that a reduction in proliferating chondrocytes
could be responsible for a reduction in long bone length and
growth.
Premature differentiation within the prehypertrophic zone
should promote bone formation and would therefore not explain
the reduction in bone size. However, increased differentiation
might lead to slower chondrocyte proliferation rates and an overall
progressive delay in ossification (should it affect the number of
proliferating chondrocytes generated over time). To address this
possibility, we asked whether a greater proportion of proliferating
chondrocyte remained in G1 state, suggestive of chondrocytes
adopting a more differentiated state in vivo. Lengthened G1 phase
has been shown to indicate differentiation status in proliferating
cells [25]. One measure of cells in proliferation versus differen-
tiation can be made through dual labeling studies using Ki67 and
BrdU. Pulsed injection of BrdU labels proliferating chondrocytes
undergoing cell division at a particular instance in time. Secondary
labeling with Ki67 at 48 hours post BrdU injection in chondrocyte
development captures a subset of BrdU+ cells that remain actively
proliferating chondrocytes, as opposed to the Ki672/low (weakly
stained) and BrdU+ chondrocytes that have adopted more
differentiated states. In theory, all the chondrocytes prior to the
hypertrophic zone continue to proliferate. However, intense
nuclear Ki67 labeling has been shown to correlate with cells in
S to M phase, and weak/negative Ki67 expression (Ki672/low)
corresponds to cells in G1/G0 phase. The greater numbers of cells
that have progressed through S/G2/M phase (BrdU+) but remain
in G1 phase (weak Ki67 labeling) corresponds to enhanced
differentiation. In this context, we observed a greater proportion of
BrdU+ and Ki672/low labeled cells in the radial bones of FlnB2/2
mice (89% in FlnB2/2 vs 69% in wild type at E16.5, and 86% in
FlnB2/2 vs 69% at P7), indicating again an increase in the number
of proliferating chondrocytes which had remained in G1 phase
and presumably adopted a more differentiated state (Fig. 4A, C). A
similar decline in the number of proliferating chondrocytes in S/
G2/M phase was seen in culture, when assessed by BrdU and
Ki67. Additionally, a similar trend toward an increased fraction of
proliferating chondrocyte cells remaining in G1 phase (BrdU+ and
Ki672/low) was observed with cultured FlnB knockout chondro-
cytes (Fig. 4B, D). Taken in the context of increased immuno-
staining for prehypertrophic markers, these studies suggest that
loss of FlnB led to an increased number of actively proliferating
chondrocytes residing in the G1 state and therefore adopting more
differentiated states.
Loss of FlnB Promotes G2/M Phase Progression and
Down-regulation of Cyclin B Associated Proteins
One possible mechanism that could account for the reduction in
proliferating chondrocytes and early differentiation would be a
role for FlnB in regulating the cell cycle, similar to that for FlnA
[12]. Loss of FlnA led to an increase in neural progenitors in G2/
M (and to a lesser degree in G1/S) phase, due to prolonged cell
cycle (through Cdk1). Cell cycle prolongation would result in
reduced proliferation and a decrease in the number of progeni-
tors/proliferating cells generated over time. In this setting,
however, increased cell cycle length would also lead to a delay
in differentiation. Flow cytometric analysis of the cell cycle by
using propidium iodide (PI) staining showed that, with FlnB
knockdown, both the S phase and the G2/M phase subpopula-
tions decreased by approximately 12% and 11% (less proliferating
chondrocytes), respectively, while the G1/G0 phase subpopula-
tions increased by approximately 23% (more differentiating/
differentiated cells) (Fig. 5A). Given the greater change seen in
G2/M phase, we then focused on Cyclin B-associated regulators of
cell cycle. Both western blotting and immunostaining results
showed a decrease in Cyclin B1 expression, which would promote
G2/M phase progression (Fig. 5B, C). To transit through the
various phases of mitosis, proliferating chondrocytes entering
metaphase must first activate Cdk1 (through dephosphorylation of
Cdk1) to initiate degradation of Cyclin B1 through the Anaphase
promoting complex (APC) system. Progression from metaphase to
anaphase and anaphase to G1 is regulated by activators of the
APC, such as Cdc20. However, expression of the APC regulator
Cdc20 was decreased in the FlnB knockdown cells, and would
therefore inhibit Cyclin B1 degradation (and therefore hinder G2/
M phase progression). Rather, phospho-Cdk1(pY15) levels were
also decreased in the FlnBsh2 cell line, whereas total Cdk1 levels
were unchanged, suggesting a role for FlnB in Cdk1 regulation. To
clarify the molecular mechanism by which FlnB regulated
Cdk1(Y15) phosphorylation, we next addressed whether loss of
FlnB altered the expression levels of several inhibitors and
activators of Cdk1 activity. In direct contrast to FlnA loss of
function in neural progenitors, inhibitors of Cdk1 activation
(enhanced phosphorylation) Wee1, Pkmyt1, and 14-3-3 were all
significantly downregulated as assessed by immunocytochemistry
Filamin B Regulates Chondrocyte Development
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and western blot analyses of the FlnBsh2 cells (Fig. 5B, C and
Supplementary Material, Fig. S5). Cdc25c levels, however, were
also down-regulated which should inhibit Cdk1 dephosphorylation
(leading to activation), suggesting that FlnB may not play a direct
role in modifying the activation/inactivation status of these
proteins. Overall, these observations implied that FlnB loss
promoted Cyclin B1 degradation by inhibiting Cdk1(Y15)
phosphorylation in proliferating chondrocytes, presumably
through some upstream pathway.
Cyclin B Associated Cdk1 Inhibition Reproduces the Loss
of FlnB Phenotypes in vitro
In order to confirm the role of Cdk1 in loss of FlnB phenotypes,
we examined ATDC5 chondrocyte proliferation and differentia-
tion following Cdk1(Y15) inhibition. Exposure of ATDC5 cultures
to as low as 1.0 mM phospho-Cdk1 (pCdk1) inhibitor (3-(2-Chloro-
3-indolylmethylene)-1,3-dihydroindol-2-one) [26] led to a signifi-
cant decrease in proliferation rate over 5 days (Fig. 6A). No
increase in cell death was observed at this low dosage of Cdk1
inhibitor (data not shown). Next, cell cycle analyses using flow
cytometry showed that both active S phase and G2/M phase
Figure 2. Premature differentiation within the prehypertrophic zone in the long bone growth plates with loss of FlnB function. (A)
Col2a1 and Col10a1 double immunostaining on P1 null FlnB radius shows an abnormally increased region of overlapping expression for the
proliferation and hypertrophic markers (open arrow). Quantitative analysis of the length of Col2a1+-Col10a1+ overlapping expression relative to the
growth plate length. The Col2a1+-Col10a1+ overlapping region is increased in FlnB2/2mice at P1 and 2 week old age (17.7% vs 8.6%, 24.2% vs 19.1%
in FlnB2/2 and wild type, respectively). The ratio at P7 shows the similar, albeit not significant, trend of change. At P1, n samples = 6, for P7 and
2 week age, n samples = 3. (B) Pthr1 antibody immunostaining. Pthr1+ zones are thickened in the FlnB2/2 radius at P1, P7 and 2 weeks. At 2 weeks,
most of the chondrocytes become Pthr1+ in some FlnB2/2 mice (open arrow). (C) Ihh antibody immunostaining. Ihh+ zones are thickened in the
FlnB2/2 radius at P1, P7 and 2 weeks. At 2 weeks, the Ihh+ zone covers both the prehypertrophic and hypertrophic zones in most of the FlnB2/2mice
(open arrow). Scale bars = 200 mm.
doi:10.1371/journal.pone.0089352.g002
Filamin B Regulates Chondrocyte Development
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e89352
Figure 3. FlnB2/2mouse chondrocytes display decreased proliferation at postnatal ages. (A) Immunostaining for Sox9 shows a decrease
in the proportion of Sox9+ cells in growth plates of FlnB2/2 mice at all detected ages. The data are quantified and graphically summarized to the
right. (B) Immunofluorescent photomicrographs of E16.5 FlnB2/2 and control radial bone growth plate after immunostaining for proliferation
markers: BrdU (fluoroscein), a marker labeling cells entering into S-phase; Ki67 (fluoroscein), a marker for cells in the cell cycle; and phospho-histone
H3 (PH3) (fluoroscein), an M-phase marker. Higher magnification images of the outlined boxes are to the right. There is an overall reduction in each of
Filamin B Regulates Chondrocyte Development
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subpopulations decreased by approximately 8% and 19% (less
proliferating chondrocytes), respectively, following treatment with
the Cdk1 inhibitor, while the G1/G0 phase subpopulations
increased by approximately 28% (more differentiating/differenti-
these markers within the proliferative zone after FlnB knockout at various ages. Statistical analyses (n$3 independent samples per experiment) shows
that the percentage of cells positively labeled for Sox9, BrdU, Ki67, and PH3 in FlnB2/2 cortex is decreased, respectively when compared to littermate
controls. * = p,0.05, ** = p,0.01, *** = p,0.001 by t-test. Scale bar = 200 mm for low magnification; 50 mm for high magnification.
doi:10.1371/journal.pone.0089352.g003
Figure 4. Increased proliferating chondrocytes remaining in G1/G0 phase in null FlnB. (A) Co-staining for Ki67 (fluoroscein) and BrdU
(rhodamine) in vivo demonstrates an increase in the number of proliferating chondrocytes in the FlnB2/2 radius that remain in G1/G0 phase,
consistent with an increased rate of differentiation. BrdU is given as a single pulse to capture the proliferating progenitors. After 48 hours, the animal
is sacrificed and co-staining is performed with Ki67 (a marker of all proliferating cells). BrdU positive progenitors, which remain as progenitors will be
Ki67 positive (Ki67hi), whereas those are undergoing differentiation (remain in G1 phase) or having been differentiated (remain in G0 phase) will be
Ki67 weak/negative (Ki672/low). Higher magnification photomicrographs of the boxed images are shown to the right and demonstrate the reduction
in BrdU+ proliferating chondrocytes, which remain Ki67hi after 48 hours with loss of FlnB. (B) Cultured primary null FlnB proliferating chondrocytes
show a similar reduction in levels of BrdU (fluoroscein) and Ki67 (rhodamine) immunolabeling. The FlnB null proliferating chondrocytes from the
culture studies also show an increase in the number of cells that remaining in G1/G0 phase (BrdU+, Ki672/low), similar to that seen in vivo. (C) and (D)
Quantification of the chondrocytes remaining in G1/G0 phase in vivo and in vitro. The analyses show an increase of approximately 10% and 13% of
BrdU+ FlnB null chondrocytes remaining in G1/G0 phase in the E16.5 and P7 radial bone, respectively (C) and an increase of approximately 36% of
BrdU+ FlnB null chondrocytes remaining in G1/G0 phase in vitro (D). * = p,0.05, ** = p,0.01, *** = p,0.001. Scale bar = 200 mm for low magnification
and 25 mm for high magnification in A; 50 mm in B.
doi:10.1371/journal.pone.0089352.g004
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ated cells)- much in the same manner and distribution as seen with
knockdown of FlnB (Fig. 6B). Further analysis of the cell cycle
markers also showed that all the cell cycle markers, Cdk1(pY15),
Cyclin B1, Cdc20 and Cdc25c, were downregulated, except that
total Cdk1 protein levels were comparable (Fig. 6C). Cdk1(pY15),
Cyclin B1, and Cdc20 were decreased by about 40%, 75% and
70%, respectively. Cdc25c levels were not quantified because of its
very low expression in FlnB knockdown groups. Cdk1 phosphor-
ylation inhibition led to a downregulation of proliferating
chondrocyte markers Col2a1 and Sox9 with ATDC5 chondro-
cytes adopting expression of markers associated with a more
differentiated chondrocyte state (Col10a1 and Runx2) (Fig. 6C).
Col2a1 and Sox9 were decreased by about 30% and 35%, while
Col10a1 and Runx2 were increased by about 75% and 40%,
respectively.
Pi3k/Akt Pathway Contributes to the Cdk1 Activity
Changes in vitro through b1 Integrin
Recognizing the changes and the contribution of Cdk1 activity
to the loss of FlnB phenotypes, we next asked whether there was a
potential mechanistic link between FlnB and Cdk1. b1 integrin is a
well known FlnA/B interactor, which also plays key roles in
regulating bone development [27,28], and our prior report had
shown that phospho-b1 integrin (pS785) was downregulated in
filamin B knockout chondrocytes [6]. We had also previously
shown that FlnB could bind b1 integrin and loss of FlnB function
led to downregulation of phospho-b1 integrin at pS785 [6]. In the
current work, we found that phospho-b1 integrin at pS785 was
dramatically decreased in the proliferating, prehypertrophic and
hypertrophic zones by immunostaining in vivo. In stable null FlnB
ATDC5 lines, we also found a reduction of protein expression for
phospho-b1 integrin at pS785 by western blotting, consistent with
our prior findings (Fig. 7A, B and C). Finally, phospho-Cdk1 levels
were decreased in the FlnB knockdown cell lines suggesting that
loss of FlnB could also indirectly effect Cdk1 activation. These
observations suggested that FlnB could influence integrin and
Cdk1 activity.
The extracellular signal related kinases (Erks) and phosphoino-
sitide 3-kinase/protein kinase B (Pi3k/Akt) pathways play key roles
in regulating bone development, function under b1 integrin
signaling, and have been implicated in the regulation of Cdk1
[29,30,31,32]. We therefore tested whether phosphorylated Erk
levels (T202/Y204), p85 subunit of Pi3k, total and phosphorylated
Akt (pS473) were changed in FlnB shRNA knockdown ATDC5
cells. Our results showed that phosphorylated Akt (pS473) but not
total Akt levels were down-regulated with loss of FlnB (Fig. 7C, E).
However, phosphorylated Erk levels did not change (Fig. 7C, E).
Thus FlnB regulates Akt but not Erk activation (i.e. phosphory-
lation).
To further address whether Akt or Erk was involved under b1
integrin signaling, we seeded control ATDC5 cells onto pre-coated
dishes with known b1 integrin activators such as collagen I,
fibronectin and laminin type I and then examined both Akt/Erk
changes as well as Cdk1 activation. Our results showed that
fibronectin and laminin type I could induce down-regulation of
Pi3k/Akt activity (no changes in total Akt), but did not induce
significant changes in Erk activity (Fig. 7D, F). Cdk1 phosphor-
ylation levels were also decreased following exposure to the
extracellular matrix molecules, suggesting that integrin could
mediate Cdk1 activity, possibly through a Pi3k/Akt pathway.
Figure 5. Dysregulation of Cyclin B-associated proteins with
loss of FlnB function. (A) Flow cytometry following propridium
iodide (PI) labeling demonstrates a decrease in the number of FlnBsh2
chondrocytes that reside in G2/M phase and an increase in the number
of cells that reside in G1/G0 phase, compared to ATDC5 control cells. (B)
Western blot analyses similarly shows a reduction in these Cyclin B1-
associated markers, including Cyclin B1, Cdc20, Cdc25c, Pkmyt1, 14-3-3,
and Wee1, within the FlnB knockdown ATDC5 cells. Cdk1 levels are
largely unchanged but Cdk1 phosphorylation (pY15) is diminished. G2/
M phase progression is mediated by Cdk1 activation (phosphorylation)
through the Cyclin B1-associated proteins. Reduced Cdk1 phosphory-
lation promotes progression through G2/M phase. Changes in Western
blot intensity for various proteins expression are quantified below. (C) A
corresponding decrease in both the rhodamine fluorescence intensity
and number of labeled FlnBsh2 proliferating chondrocytes is seen using
various G2/M phase markers, including Cyclin B1, Cdc20, and Cdc25c
(rhodamine). Additional markers are shown in supplementary figure S5.
* = p,0.05, *** = p,0.001. Scale bar = 50 mm in C.
doi:10.1371/journal.pone.0089352.g005
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We next tested whether Erk or Pi3k/Akt signaling could induce
Cdk1 activity changes in ATDC5 cells, as well as alter the
differentiation state of the proliferating chondrocytes. The Erk
activator TPA and Erk inhibitor U0126 were added into ATDC5
cell cultures but no significant Cdk1 activity changes were
observed in either group (Supplementary Material, Fig. S6).
However, the pAkt inhibitor VIII could not only induce
downregulation of phospho-Cdk1(pY15), but also induced down-
regulation of Sox9 levels and up-regulation of chondrocyte
differentiation markers Runx2 and Col10a1 (Fig. 7G). Collective-
ly, these studies suggested that Pi3k/Akt pathway mediated the b1
integrin signaling to the Cdk1 activity. Moreover, FlnB regulation
of b1 integrin levels would suggest that FlnB could also indirectly
influence Cdk1 activity through this pathway.
Discussion
Our current work demonstrates that FlnB regulates Cdk1
phosphorylation levels, potentially through extracellular matrix
mediated activation of b1 integrin and Pi3k/Akt. Cdk1 phos-
phorylation oversees proliferating chondrocyte progression
through the G2/M phase of the cell cycle and differentiation.
Thus, the thickened prehypertrophic zone, seen with loss of FlnB,
reflects premature differentiation of proliferating chondrocytes.
This premature differentiation also leads to a decrease in
proliferation, a progressive decline in chondrocyte production
over time, and ultimately a delay in bone growth. These findings
provide a mechanistic explanation for the seemingly opposite
phenotypes of early differentiation but delayed skeletal formation.
Filamin B Regulates Chrondrocyte Proliferation and Long
Bone Growth
FlnB loss of function in mice causes shortening of the skeletal
appendicular bones and a delay in skeletal development over time
[5,6,7,8]. The current studies suggest that a progressive decline in
the rate of proliferation may be responsible for limiting bone
growth. We observed a decrease in various proliferation markers
over time, including BrdU, Ki67 and PH3 [33,34,35]. The loss of
proliferating cell numbers could extend from either prolongation
of the cell cycle, early differentiation and/or increased cell death.
TUNEL staining of null FlnB growth plates, however, did not
suggest an increase in the number of apoptotic proliferating
chondrocytes (data not shown). FlnB-knockdown ATDC5 prolif-
erating chondrocytes did exhibit slower rates of proliferation with
an apparent increase of G1/G0 phase subpopulations and a
Figure 6. Cdk1 inhibition reproduces the loss of FlnB phenotypes. (A) Following inhibition of Cdk1 activity, ATDC5 progenitors undergo a
slower growth rate compared to untreated ATDC5 controls. Proliferation capacity is dramatically decreased at low concentrations of Cdk1 inhibitor
(1 mM) and in the absence of any observed increase in cell death. (B) Flow cytometry following propridium iodide (PI) labeling shows a decrease in
the number of ATDC5 cells in G2/M phase and an increase in the number of ATDC5 cells in G1/G0 phase in the Cdk1 inhibitor (1 mM) treated cells
compared to control. (C) All the cell cycle markers, Cdk1(pY15), Cyclin B1, Cdc20 and Cdc25c, are downregulated following Cdk1 inhibitor treatment,
with the exception of total Cdk1 protein levels. Quantification graph is shown to the right. As seen with loss of FlnB function, inhibition of Cdk1
activity (phosphorylation) leads to a decline in early progenitor markers Sox9 and Col2a1, and upregulation of hypertrophic markers Col10a1 and
Runx2. Quantitative changes are shown graphically to the right. * = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0089352.g006
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decrease of G2/M phase subpopulations, suggesting that more
cells remained in G1/G0 phase and were undergoing differenti-
ation. Accordingly, we observed early onset differentiation as
evidenced by a decline in expression of earlier markers and
increase in more mature chondrocyte markers. Moreover,
chondrocytes with knockdown of FlnB showed downregulation
of G2/M phase cell cycle markers, including Cyclin B1 and Cdc20
[36,37,38,39]. These observations would indicate that increased
maturation of the proliferating chondrocytes leads to slower
proliferative rates and hence reduced chondrocyte production. In
short, slower proliferation through increased chondrocyte matu-
Figure 7. Loss of FlnB induces Cdk1 activity changes through b1 integrin-Pi3k/Akt pathway. (A, B) Immunostaining of total and phospho-
b1 integrin (pS785)(postnatal day 1 radius). Phospho-b1 integrin (pS785) levels are down-regulated in FlnB knockout chondrocytes (arrows) (B). (C, E)
Western blotting results show that Pi3k(p85 subunit) and phospho-Akt(pS473), as well as phospho-Cdk1(pY15) are down-regulated in FlnB
knockdown (Bsh) ATDC5 cells. Total Akt levels are not changed. Total b1 integrin levels are up-regulated but phospho-b1 integrsin (pS785) are down-
regulated. Results are quantified in (E). (D, F) b1 integrin activation (Itgb1) in ATDC5 cells regulates Pi3k/Akt and Cdk1 activation. Pretreatment of
ATCD5 cells with fibronectin and laminin I but not collagen (col) induces up-regulation of total b1 integrin levels but down-regulation of phospho-b1
integrin (pS785) levels. Pi3k, pAkt and Cdk1(pY15) levels are down-regulated by fibronectin and laminin I. Total Akt levels are not changed. ATDC5
cells are incubated in the presence of extracellular matrix molecules: fibronectin, laminin, and collagen, which serve as ligands for the b1 integrin
receptor, and activation of the downstream pathways are assessed by Western blot analyses. Con= control, Col = collagen, Fib = fibronectin, and
Lam= laminin. (G) Pretreatment of ATDC5 cells with Akt inhibitor VIII decreases Akt(pS473), Cdk1(pY15) and Sox9 levels, but increases protein levels
of hypertrophic markers such as Runx2 and Col0a1. * = p,0.05, ** = p,0.01, *** = p,0.001; ##=p,0.01, ###=p,0.001. Star sign (*) represents
comparison with control groups. (#) represents comparison between FlnA knockdown groups and FlnB knockdown groups. Scale bars = 200 mm, in A
and B.
doi:10.1371/journal.pone.0089352.g007
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ration at least partially contributes to the observed skeletal
phenotype.
Loss of FlnB Promotes Chondrocyte Differentiation
FlnB loss of function can cause bone fusion accompanied by
enhanced chondrocyte hypertrophy and premature differentiation
[5,6,7,8]. Loss of FlnB leads to premature differentiation with a
widening of the prehypertrophic zone, as evidenced by an increase
in immunostaining for the prehypertrophic (Pthr1 and Ihh)
markers. We also observed an increase in overlap in the number
of chondrocytes staining for both the proliferative (Col2a1) and
hypertrophic (Col10a1) zone markers in FlnB2/2 mice, indicating
some disruption in this intermediate stage of differentiation. The
relative decrease in Col10a1 vs Col2a1 lengths with loss of FlnB
would also argue that the greater defect lies in the transition from
the proliferative to prehypertrophic zones, although these studies
did not address whether there was any dysregulation in
chondrocyte differentiation from the prehypertrophic to hyper-
trophic zones. That said, the FlnB knockdown ATDC5 cells
showed characteristics of more terminal hypertrophic differentia-
tion with increases in Col10a1, accompanied by decreases in the
prehypertrophic markers Pthr1 and Ihh, when compared to the
in vivo data. This observation indicates that chondrocytes ulti-
mately undergo either normal or enhanced hypertrophic differ-
entiation. Given that the ATDC5 cells do not undergo mineral-
ization, the increase in hypertrophic phenotype could merely
reflect this progressive differentiation. Somewhat surprisingly, our
data show that the alkaline phosphatase activity was decreased
rather than increased in the FlnB knockdown ATDC5 cells, in
contrast to the upregulation of Col10a1 and Runx2. Given that
alkaline phosphatase is a mineralization marker, the downregula-
tion of alkaline phosphatase activity was actually consistent with
our finding of a delay in bone formation. These results would
suggest that FlnB promotes partial but not full chondrocyte
hypertrophy. Overall, the accelerated premature differentiation
seems to cause a slowing in the proliferative rate of the
proliferating chondrocyte pool in the growth plate and ultimately
delay bone growth.
FlnB Regulates Chondrocyte Proliferation and
Differentiation through Cell Surface Receptors
Two primary cell surface receptors have been implicated in
FlnB-dependent regulation of chondrocyte differentiation. Recent
work suggested that loss of FlnB leads to accumulation of phospho-
Smad3 (through activation of the transforming growth factor beta
receptor 1, Tgfbr1) [7]. Phospho-Smad3 promotes Runx2
function and early chondrocyte differentiation [7]. However, loss
of TGF-b–Smad3 signaling also promotes chondrocyte hypertro-
phy, suggesting other regulators of this pathway. Prior studies from
our laboratory and others have also shown that FlnB binds b1
integrin. Loss of b1 integrin function in chondrocytes leads to a
progressive delay in chondrocyte differentiation within the
hypertrophic zone and widening of prehypertrophic zone.
Filamins play crucial roles in integrin regulation by either
inhibiting integrin activation through C terminal binding or
promoting integrin trafficking to plasma membrane for cell
spreading [40]. These findings would indicate a more fundamental
role for filamins near the cell surface in the regulation of various
receptors and indirectly regulate the cell cycle and proliferation.
Prior reports have implicated FlnB-Smad3 interactions in
inhibiting the downstream transcription factor Runx2 and
promoting the null FlnB skeletal phenotype [7]. Runx2 promotes
chondrocyte hypertrophy, and inhibition of Runx2 in the FlnB2/2
mice appears to rescue some of the aberrant mineralization due to
premature chondrocyte hypertrophy. However, inhibition of
Runx2 still does not rescue the overall skeletal length, suggesting
that Runx2 might play a partial causal role [7]. Smad 2,3 has
previously been shown to regulate Cyclin D/E (regulators of G1 to
S phase transition) whereas b-integrins mediate Cyclin B
(regulators of G2/M) and D/E. Both Akt and Runx2 have been
implicated in regulation of Cyclin B/D activity. The current
studies indicate that FlnB-b1integrin interactions enhance activa-
tion of the Pi3k/Akt pathway, which promotes endochondral bone
growth. Our studies would suggest that Akt directs CyclinB/Cdk1
dependent progression through G2/M phase. In this respect, FlnB
likely binds and regulates activation of receptors (such as Smad
and integrins) near the cell surface [6,7,32,41]. These receptors
mediate downstream mechanisms (Runx2 and/or Pi3k/Akt),
which regulate chondrocyte proliferation and differentiation
through cyclin-associated proteins. Phospho-Akt (pS473) changes
were not observed in FlnB2/2 fibroblasts [8] suggesting that these
changes might be cell specific or might reflect the observation that
FlnB is preferentially expressed in bone (unpublished observa-
tions).
Mechanisms Underlying FlnA/B in Regulation of Cell
Cycle
The mechanisms by which filamins regulate CyclinB-Cdk1
activity in proliferating chondrocytes are likely complex. Our prior
work has suggested that FlnA physically interacts with several
Cyclin B associated proteins (such as Wee1) [12]. Moreover, FlnA
impairs the degradation of these proteins that directly regulate
Cdk1 phosphorylation. The current studies indicate that FlnB
influences Cdk1 activity more indirectly than directly through its
interactions with integrins at the cell surface. Integrin activation
leads to downstream inactivation of various kinases (such as Akt)
which direct Cdk1 function [29,31,32]. Finally, FlnA physically
binds to FlnB to form heterodimers and this interaction likely
influences both the dynamic activation of receptors at the cell
surface and clearance of cyclin B associated proteins.
How FlnA and FlnB differentially mediate proliferation and
development may be of some importance. We have recently
shown that loss of FlnA results in an increased number of cells
residing in G2/M phase, and to a lesser degree, in G1/S phase-
thereby leading to a prolongation of the cell cycle and delayed
differentiation [12]. The delay in progression through G2/M
phase was due to impaired degradation of Wee1 (a Cyclin B-
associated protein) and consequent increase in phospho-Cdk1.
The current studies demonstrate that in some fashion, loss of FlnB
leads to a directly opposite phenotype with fewer proliferating
chondrocytes residing in G2/M phase (promoting cell cycle
progression), and premature differentiation.
The current observations raise the question as to how the
balance between FlnA and FlnB is tightly controlled and how their
differential roles are integrated coordinately during development.
Several studies have implicated FlnA in regulation of endosomal
vesicle trafficking through the caveolin pathways, suggesting that
stabilization or activation of cell surface receptors such as b1
integrin [32] or TGFb1 (Smad) [41] may be dependent on the
filamins. Alternatively, we have observed a role for FlnA in
ubiquitination (data not shown) and filamins have been linked to
E3 ligases in the ubiquitin pathway [42], raising the possibility that
these proteins could mediate the clearance of the cyclin associated
proteins. In this respect, FlnA may enhance degradation of specific
cell cycle proteins whereas FlnB may antagonize this role. Future
studies will be required to evaluate the relationship between FlnA
and FlnB in regulating these pathways.
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Materials and Methods
Ethics Statement
All mouse studies were performed under approval from the
Institutional Animal Care and Use Committees of Harvard
Medical School and Beth Israel Deaconess Medical Center in
accordance with The National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
FlnB2/2 Mice Breeding, BrdU Injections, Tissue Isolation
and Bone Decalcification
The FlnB2/2 mice were generated and bred as previously
reported [6]. The wild-type allele was detected by PCR
amplification using the primer pair 59-agattattcacccggacgtg-39
and 59-cctgggctaataatggcaga-39, and the mutated allele by using
59-ctgtgctcgacgttgtcactg-39 and 59- gatcccctcagaagaactcgt-39. For
the in vivo chondrocyte proliferation assays, E14.5, E16.5 pregnant
mice or P7 newborn mice were injected with BrdU at 50 mg/kg
ip. after plugging date, and the mice were sacrificed after 3 or 48
hours. Ketamine/Xylazine combination was used for anesthesia
and euthanization (100 mg/kg and 10 mg/kg, 400 mg/kg and
40 mg/kg, respectively, injected intraperitoneally). Tissues were
isolated after euthanization and fixed with 4% paraformaldehyde
or 10% trichloroacetic acid. Additional samples were frozen,
sectioned, and fixed prior to staining. Young and adult tissues were
further decalcified by 5% trichloroacetic acid solution containing
1% HCl and 1% acetic acid for 7 days.
Skeletal Staining, Routine Histology, Immunostaining
and Imaging
Skeletal staining and routine histology, immunostaining of the
radial bones was previously performed in this laboratory [6]. In
brief, different age wild-type and mutant mice were euthanized as
above, forearms dissected, skinned and eviscerated, and the
skeleton was dehydrated in 95% ethanol overnight and acetone
overnight. The radial bones were then stained with Alizarin red
(0.005%) and Alcian blue (0.015%) in a solution containing
ethanol, glacial acetic acid and water (60:5:35) at 37uC overnight.
The stained embryos were then transferred to 1% potassium
hydroxide solution for 7 days to dissolve the soft tissue. The
skeletal bones were preserved in glycerol.
Conventional HE staining methods with mild modifications was
used. In brief, bone tissues were fixed with 10% (w/V)
trichloroacetic acid (TCA) for more than 24 hours and then
decalcified with 5% TCA solution containing 1% HCl and 1%
acetic acid for 7 days. 18 micron frozen sections were placed into
water for 5 minutes, then stained with 16Hematoxylin solution
(Cat.# HHS32, Sigma, St. Louis, MO, USA) for 3 minutes. After
water washing, sections were place in 3% acetic acid/70% ethanol
v/v solution. After washing in water, samples were incubated with
Scott’s solution for 30 seconds. After water washing and 95%
ethanol incubation, sections were stained with alcoholic Eosin Y
for 3 minutes. Finally, after serial dehydration through graded
ethanol solutions, sections were rinsed in xylene and mounted with
cytoseal 60 (Richard-Allan). Images were obtained with an
Axioskop microscope (Zeiss, Germany).
For immunostaining of FlnB, Sox9, Pthr1, Col2a1, Col10a1,
Runx2, Cdk1(pY15), Cyclin B1, Cdc20, Cdc25c, Wee1 and
Pkmyt1, tissues and cells were fixed using 10% (w/V) ice-cold
TCA for 20 minutes. For staining of other antibodies, the samples
were fixed with 4% paraformaldehyde for 10 minutes. After
washing in PBS, fixed samples were permeabilized with 0.5%
Triton X-100 and blocked with 5% normal horse serum for 2
hours. Tissue was incubated with the primary antibodies for
1 hour at room temperature or overnight at 4uC. The Dylight488-
and Dylight594-conjugated secondary antibodies (Jackson Im-
munoresearch, West Grove PA, USA) were incubated for 1 hour
at room temperature. Samples were further counterstained with
100 ng/ml Hoechst33342 (Life Technologies, Grand Island, NY,
USA). Images were obtained with an LSM5 Pascal confocal
microscope (Zeiss, Germany). The staining intensity was analyzed
by histogram signal intensity using Adobe Photoshop(each growth
plate is divided into 30 fractions from the secondary germinal
center to the border of the hypertrophic zone as labeled in each
panel, and the signal intensity(luminosity) is determined with
Adobe Photoshop Histogram Tool. The primary antibodies (for
immunostaining and some also for western blotting) were: rabbit
anti-FlnA monoclonal antibody (1:300, Cat.# 2242, Epitomics,
Burlingame, CA, USA); rabbit anti-FlnB polyclonal antibody
(Gifted by Dr. Kao, CWRU); mouse anti-Col2a1 (Cat.# Ab3092,
ABCAM, USA); rabbit anti-Col10a1 (kindly gifted by Dr. Horton
and Dr. Lunstrum, Shriners Hospital for Children, Portland, OR,
USA; [21]); rabbit anti-Pthr1 (Cat.# Ab75150, ABCAM,
USA);rabbit anti-Ihh (Cat.# sc-13088, Santa Cruz); rabbit anti-
Runx2 (Cat.# sc-10758, Santa Cruz); rabbit anti-Sox9 pab (1:300,
AB5535, Millipore); rabbit anti-Sox9 pab (O9-1, gift of Professor
Dr. Michael Wegner, Institute of Biochemistry, Friedrich-Alexan-
der-University, Erlangen-Nurnberg, Germany); rat anti-BrdU
(1:150, Cat.# MCA2060, AbD Serotec, Raleigh, NC, USA);
rabbit anti-Ki-67 mab (1:200, Cat.# 4203, Epitomics); rabbit anti-
PH3 pab (1:250, Cat:# 06-570, Millipore, Billerica, MA, USA);
mouse and rabbit anti-Wee1 (1:50, Cat.# sc-5285 and sc-325,
Santa Cruz); rabbit anti-Pkmyt1 (1:100, Cat.# 3303, Epitomics);
anti-pan 14-3-3 (Santa Cruz, sc-629); mouse and rabbit anti-cyclin
B1 (1:100, Cat.# sc-245 and sc-752, Santa Cruz); mouse anti-
Cdc20 (1:100, Cat.# sc-13162, Santa Cruz); mouse and rabbit
anti-cdc25c (1:100, Cat.# sc-55513 and sc-327, Santa Cruz);
rabbit-anti-Cdk1 (Cat.# PC25,Calbiochem, San Diego, CA,
USA); mouse anti-Cdk1(pY15) (Cat.# BD612306, BD, Franklin
Lakes, NJ USA); rabbit anti-Pi3k (p85 subunit alpha, Cat#: 1675,
Epitomics); rabbit anti-Akt (phospho-S473, Cat# 4060, Cell
Signaling); rabbit anti-Erk1/2 (phospho-T202/Y204, Cat.#
4370, Cell Signaling); rat anti-b1 integrin (Cat.# mab1997,
Millipore); rabbit anti- b1 integrin(pS785) (Cat.# OPA1-03177,
Affinity BioReagents). In situ hybridization studies for Ihh, Col2a1
and Col10a1 have been previously described [5,6].
Mouse Primary Chondrocyte Isolation and Cell Culture
Primary chondrocytes from growth plates of newborn mice
were prepared according to the Lefebvre’s protocol [43] with mild
modifications [6]. In brief, the growth plates of radius and ulna
were dissected from P7 newborns, minced and washed in cold
Hanks buffered saline solution, and placed in 0.2% collagenase
type I (Cat.# 4196, Worthington, Lakewood, NJ, USA) solution in
DMEM at 37uC for 3 hours. Soft tissues were detached from
cartilage by repeated pipetting; the sediment cartilage was further
digested with 0.2% collagenase I for 6 hours. The dissociated cells
were then passed through a cell strainer to isolate single cells and
were plated at feasible density in DMEM with 10% FBS.
ATDC5 Cell Culture and Proliferation Analysis
Mouse ATDC5 chondrocyte cells (Cat# 99072806, Sigma) and
shRNA expressing ATDC5 cells were cultured in DMEMmedium
containing 10% fetal bovine serum, 100 IU/ml penicillin, and
100 mg/ml streptomycin (Cat.# 15140, Invitrogen). Unless
otherwise specified, ATDC5 cells were passaged every two days.
For cell growth curve test, 16105 ATDC5 cells/well were seeded
into 12-well plates and incubated for 6 days. Triplicate wells for
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each time points were used. Cell numbers were counted everyday.
For BrdU incorporation test, 10 mM BrdU was added to the
ATDC5 cells growing on cover slips for 1 hour and labeled with
rat-anti-BrdU antibody.
shRNA Vector Construction, Lentivirus Preparation and
Infection
Two sets of shRNA target sequences were designed and
corresponding oligomers were synthesized. The shRNA sequences
were: shRNA1, 59-gccgacattgaaatgccgttt-39; shRNA2, 59-gcccaaat-
caagactcttaat-39. After heating to 98uC for 10 minutes, the
oligomers were reannealed in boiling water that gradually cooled
back to room temperature, followed by gradual cooling back to
room temperature. Then the annealed products were ligated into
the HpaI/XhoI sites of the EGFP tagged pSicoR lentivirus vector.
The helper vectors, pD8.9 and pVSVG were transfected together
with the lentivirus vector into 293T cells. For the control group,
empty pSicoR vector was used. The TransFectin Lipid reagent
was used according to manufacturer’s instructions (Cat.# 170-
3352, BIO-RAD). Lentivirus containing medium was collected by
centrifugation at 20006g for 10 minutes. Then the supernatant
was passed through a 0.45 um filter. The filtered medium was
directly added to the pre-seeded ATDC5 cells. The infected
ATDC5 cells were visualized by microscope and were verified by
confocal scanning. After two rounds of infection, all the ATDC5
cells were EGFP positive. The EGFP positive ATDC5 cells were
used for further in vitro experiments. Several additional lines were
generated in parallel fashion, including null FlnA lines which
served as comparative controls.
Cdk1 Inhibition, Akt Inhibition, b1 Integrin Activation, Erk
Activation and Inhibition
A Cdk1 phosphorylation inhibitor (3-(2-Chloro-3-indolylmethy-
lene)-1,3-dihydroindol-2-one, 50 mM) was dissolved in DMSO
and added into cultured ATDC5 cells at final concentrations of
5 mM, 3 mM and 1 mM for titration. The Cdk1 inhibitor at 1 mM
did not induce cell death in ATDC5 cells and this concentration
was used for cell growth curve analysis and differentiation
induction analysis. The Cdk1 inhibitor was added to cells and
incubated for 6 days for cell growth curve analysis with daily
quantification of cell numbers. For differentiation induction
analyses, the Cdk1 inhibitor was added and cells were incubated
for 6 days, with the cells being passaged every two days. For b1
integrin activation, culture dishes were pre-coated with Collagen I
(cat#: 354236, BD Biosciences), fibronectin (F0895, Sigma) and
laminin type I (Cat#: 354232, BD Biosciences) following
manufacture’s instructions. ATDC5 cells were incubated for 4
hours and 48 hours respectively and were collected for western
blotting analysis. Erk activator TPA (12-O-Tetradecanoylphorbol-
13-Acetate, 200 nM, Cell Signaling) and Erk inhibitor U0126
(10 mM, Cell Signaling) were added into cultured ATDC5 cells for
30 minutes and 24 hours respectively for Erk and Cdk1 activity
analysis. Akt inhibitor VIII (Isozyme-Selective, Akti-1/2, Cat#
124018, Millipore) was dissolved in DMSO and added into
cultured ATDC5 cells at final concentration of 10 mM for 48
hours for Akt(pS473), Cdk1(pY15) and differentiation analysis.
The same volumes of DMSO were added as controls for signaling
activation and inhibition tests.
RT-PCR
Total RNA samples were prepared from ATDC5 cells and
shRNA expressing ATDC5 cells. The RNA was extracted from
adult tissues using TRIzol (Invitrogen). Reverse transcription and
PCR were performed as conventional methods by using Super-
Script III First Strand Kits (Cat# 18080-400, Invitrogen). The
cDNA was amplified by PCR for 30 cycles. Primers were selected
encompassing the intron sequences. The primer sequences used
for FlnB RT-PCR analysis were: forward, 59-tcttcccacatacgatgcaa-
39; reverse, 59-tccactacaaagcccacctc-39. The Gapdh was used as
internal control and the primers were: forward, 59-ggcaaagtgga-
gattgttgcc-39; reverse, 59-aagatggtgatgggcttcccg-39. PCR cycling
was performed at 95uC for 2 minutes followed by 95uC for 30
seconds, 55uC for 30 seconds, 72uC for 1 minutes, and finally
72uC for 6 minutes, by using the EmeraldAmp MAXPCR master
mix (Takara, Cat.# RR320A, Japan). PCR products were
analyzed by 1.5% agarose gel.
Immunoprecipitation and Western Blotting
Samples were collected either immediately or 36 hours after
transfection. Modified RIPA buffer (50 mM Tris-HCl, pH7.5;
150 mM NaCl, 1.0% Triton x-100; 0.5% sodium deoxycholate
and 0.1% SDS), with proteinase inhibitor cocktail and protein
phosphotase inhibitor cocktail, as well as additional NaF (10 mM)
and Na3VO4 (1 mM), was used for cell lysis. Conventional
immunoprecipitations were performed by using Protein-A/G
ultralink resin beads according to the protocol provided by the
manufacturer (Cat.# 53132, Thermo Scientific, Rockford, IL,
USA Proteins were separated in 8% or 10% SDS-polyacrylamide
gels and transblotted to PVDF membrane. Immunoblot analysis
was performed with primary antibodies based on manufactures’
guides or suggested dilutions. Blots were detected by using
LumiGOLD ECL western blotting detection kit (Cat.#
SL100309, SignaGen, Rockville, MD, USA).
Alkaline Phosphatase Assay
Alkaline phosphatase activity was determined by using alkaline
phosphatase assay kit (Cat# ab83369, ABCAM) following
manufacture’s instructions. In brief, cultured control and FlnB
knockdown ATDC5 cells (16106) were homogenized with assay
buffer after cold PBS washing. For each sample, 10, 20, 30, 40 and
50 ml of supernatant were added into triplet 96-wells and each well
was brought to a total volume of 80 ml with assay buffer. Triplets
of 30 ml of each sample were added into 96-wells and 50 ml of
assay buffer was added, followed by adding 20 ml of stop-solution
for background control. Standard curves were generated as
manufacture’s guide. The alkaline phosphatase enzyme activity
of each sample was calculated based on the comparison between
standard curve and sample curve, and was shown as Unit/ml (U/
ml).
Statistical Analyses
Results were expressed as the mean6s.d. of n experiments (n$
3). For section staining, unless otherwise specified, 3 animals were
used for each experiment and 3–4 sections were stained per
animal. For cultured cell staining, cells were plated and growing
on 3 coverslips per sample. For cell growth curve analysis, 3
independent experiments were performed, with 3–4 wells were
collected from each sample at each time point. Statistical analysis
was performed with Student’s t-test, with P,0.05 considered
significant. For quantitative analyses of immunostaining results,
luminosity (histogram value, Adobe photoshop) values were
obtained and based on the threshold (luminosity value 20) cells
were grouped into highly stained and weakly/negatively stained
subpopulations. For quantitative analyses of western blotting
results, band intensity was obtained by subtracting background
luminosity from the total luminosity of each band (histogram
value, Adobe photoshop).
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Figure S1 FlnB knockdown efficiency in ATDC5 chon-
drocyte progenitors.
(DOC)
Figure S2 FlnB2/2mice display skeletal shortening and
abnormalities in the growth plates of the appendicular
bones.
(DOC)
Figure S3 FlnB2/2 mice display reduced Col10a1+/
Col2a1+ ratio in the growth plates of the appendicular
bones.
(DOC)
Figure S4 Increased differentiation with loss of FlnB
function in the long bone.
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Figure S5 Diminished expression of Cyclin B-associat-
ed proteins in FlnB knockdown chondrocyte progeni-
tors.
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Figure S6 Erk activation and inhibition assay.
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